The side effects of translational omics: Overtesting, overdiagnosis, overtreatment

Clinical Chemistry and Laboratory Medicine

Volumn 54, Issue 3, 2016, Pages 389-396

  Diamandis, Eleftherios P ^a,b,c   Li, Michelle ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

escape from cure; high throughput omics; incidental findings; indolent disease; overdiagnosis; overtesting; overtreatment; side effects

Indexed keywords

ARTICLE; BIOMICS; CANCER SCREENING; DISEASE PREDISPOSITION; FALSE POSITIVE RESULT; HUMAN; INCIDENTALOMA; MASS SCREENING; MORBIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRANSLATIONAL OMICS; WHOLE GENOME SEQUENCING; GENETICS; GENOMICS; HEALTH SERVICE; NEOPLASMS; PROTEOMICS;

GENOMICS; HUMANS; MEDICAL OVERUSE; NEOPLASMS; PROTEOMICS;

EID: 84958811573     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2015-0762     Document Type: Article

References (47)

1. Hood L, Balling R, Auffray C. Revolutionizing medicine in the 21st century through systems approaches. Biotechnol J 2012;7:992-1001.
2. Flores M, Glusman G, Brogaard K, Price ND, Hood L. P4 medicine: how systems medicine will transform the healthcare sector and society. Per Med 2013;10:565-76.
3. Xu S, Zhang Y, Jia L, Mathewson KE, Jang K-I, Kim J, et al. Soft microfluidic assemblies of sensors, circuits, and radios for the skin. Science 2014;344:70-4.
4. Gibbs WW. Medicine gets up close and personal. Nature 2014;506:144-5.
5. Hood L, Lovejoy JC, Price ND. Integrating big data and actionable health coaching to optimize wellness. BMC Med 2015;13:4.
6. Kaiser J. Google X sets out to define healthy human. Science insider 2014. Available from: http://scim.ag/googlehuman.
7. Diamandis EP. The hundred person wellness project and Google's baseline study: medical revolution or unnecessary and potentially harmful over-testing? BMC Med 2015;13:5.
8. Wilcken B. Newborn screening: gaps in the evidence. Science 2013;342:197-8.
9. Wilson MG, Jungner G. Principles and practice for screening for disease. Public Health Papers 34; Geneva: World Health Organization, 1968.
10. Welch HG. Overdiagnosis and mammography screening. Br Med J 2009;339:182-3.
11. Skeggs LT Jr. Persistence...and prayer. From the artificial kidney to the autoanalyzer. Clin Chem 2000;46:1425-36.
12. Anonymous. Bargain genome. Nature 2014;505:458-9.
13. Chrystoja CC, Diamandis EP. Whole genome sequencing as a diagnostic test: challenges and opportunities. Clin Chem 2014;60:1-10.
14. Yang Y, Muzay DM, Reid JG, Bainbridge MN, Willis A, Ward PA, et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N Engl J Med 2013;369:1502-11.
15. Esplin ED, Oei L, Snyder MP. Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease. Pharmacogenomics 2014;15:1771-90.
16. Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, et al. Whole-exome sequencing and clinical inter pretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 2014;20:682-8.
17. Garralda E, Paz K, López-Casas PP, Jones S, Katz A, Kann LM, et al. Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment. Clin Cancer Res 2014;20:2476-84.
18. Ellis MJ. Mutational analysis of breast cancer: guiding personalized treatments. Breast 2013;22:S19-21.
19. Anonymous. The FDA and me. Nature 2013;504:7-8.
20. Annas GD, Sherman E. 23andMe and the FDA. N Engl J Med 2014;370:985-8.
21. Church G. Genomics is mired in misunderstanding. Nature 2013;502:143.
22. Roberts NJ, Vogelstein JT, Parmigiani G, Kinzler KW, Vogelstein B, Valculescu VE. The predictive capacity of personal genome sequencing. Sci Transl Med 2012;4:133ra58.
23. Castle PE. Teaching moment: why promising biomarkers do not always translate into clinically useful tests. J Clin Oncol 2014;32:359-61.
24. Esserman LJ, Thompson IM Jr, Reid B. Overdiagnosis and over-treatment of cancer. An opportunity for improvement. J Am Med Assoc 2013;310:397-8.
25. Schiffman M, Solomon D. Cervical - cancer screening with human papillomavirus and cytologic cotesting. N Engl J Med 2013;369:2324-31.
26. Levin TR, Corley DA. Colorectal - cancer screening - coming of age. N Engl J Med 2013;396:1164-6.
27. Kistler CE. Colorectal - cancer incidence and mortality after screening. N Engl J Med 2013;396:2354-5.
28. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast - cancer incidence. N Engl J Med 2012;367:1998-2005.
29. Biller-Andorno N, Juni P. Abolishing mammography screening programs. A view from the Swiss Medical Board. N Eng J Med 2014;370:1965-7.
30. Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, et al. Results of the two incidence screenings in the national lunch screening trial. N Engl J Med 2013;369:920-31.
31. Maldonado F, Peikert T, Midthun D. Cancer in pulmonary nodules detected on first screening CT. N Engl J Med 2013;396:2060-1.
32. McWilliams A, Tammemagi MC, Mayo JR, Roberts H, Liu G, Soghrati K, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med 2013:369:910-9.
33. Moyer VA. Screening for lung cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2014;160:330-8.
34. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK collaborative trial of ovarian cancer screening (UKCTOCS). Lancet Oncol 2009;10:327-40.
35. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009:360:1310-9. Erratum in: N Engl J Med 2009;360:1797.
36. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
37. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-90. Erratum in: N Engl J Med 2012;366:2137.
38. Wade J, Rosario DJ, Macefield RC, Avery KN, Salter CE, Goodwin ML, et al. Physchological impact of prostate biopsy: physical symptoms, anxiety, and depression. J Clin Oncol 2013;31:4235-41.
39. Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, Parnes H, et al. Screening for prostate cancer with prostate-specific antigen testing: American society of clinical oncology provisional clinical opinion. J Clin Oncol 2012;30:3020-5.
40. Thompson IM, Tangen CM. Prostate cancer - uncertainty and a way forward. N Engl J Med 2012;376:270-1.
41. Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. J Am Med Assoc 2014;311:1143-9.
42. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203-13.
43. Froehner M, Writh MP. Early prostate cancer - treat or watch? N Engl J Med 2011;365:568-9.
44. Solomon BD. Incidentalomas in genomics and radiology. N Engl J Med 2014;370:988-90.
45. MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis GR, et al. Guidelines for investigating causality of sequence variants in human disease. Nature 2014;508:469-76.
46. Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, et al. Eight-year results of randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989;320:822-8.
47. Anonymous. Prostate cancer: send away the PSA? Lancet 2012;380:307.